Cytokinetics, Incorporated
CYTKNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $8.23B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $54.30$88.31
- Volume (live)
- -
- Avg. volume (3M)
- 2.10M
Cytokinetics, Incorporated (CYTK) Stock Price & Financial Analysis
Cytokinetics, Incorporated Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $61.94 - $64.07 |
|---|---|
| 52-Week High | $88.31 |
| 52-Week Low | $54.30 |
| Open | $63.01 |
| Volume (last close) | 2.06M |
| Average Volume (3M) | 2.10M |
| Revenue (TTM) | 67.67M |
|---|---|
| Net Income (TTM) | -894.00M |
| Free Cash Flow (TTM) | -580.71M |
| EPS (TTM) | −$7.18 |
| Profit Margin | -1321.12% |
| Operating Margin | -1046.12% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 8.23B |
|---|---|
| Shares Outstanding | 132.09M |
| Price to Sales (P/S) | 121.66 |
| Price to Book (P/B) | -47.46 |
| EV/EBITDA | -11.37 |
| 50-Day MA | $69.71 |
|---|---|
| 200-Day MA | $70.14 |
| 1-Year Change | +8.40% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Cytokinetics, Incorporated at a Glance
As of the Oct 22, 2026 close, Cytokinetics, Incorporated (CYTK) has a market capitalization of $8.23B. The stock trades at 121.7× sales. Over the trailing twelve months it lost $894.00M on revenue of $67.67M and burned $580.71M of free cash flow. Revenue fell 21.1% year over year.
As of its latest reported balance sheet, it holds $255.27M in cash and securities against $1.15B of debt, a net debt position of $891.82M.
Cytokinetics, Incorporated does not currently pay a dividend.
The share price is up 8.4% over the past year. At $62.33 (the Oct 22, 2026 close) it sits within its 52-week range of $54.30 to $88.31, below its 200-day moving average of $70.14.
Based on 17 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $111.21, 78.4% above the Oct 22, 2026 close.
Frequently Asked Questions About Cytokinetics, Incorporated
What is the current stock price for CYTK?
As of the Oct 22, 2026 close, CYTK stock trades at $62.33. The 52-week range is $54.30–$88.31, with a day range of $61.94–$64.07.
What is the P/E ratio for CYTK?
The P/E ratio (Price-to-Earnings) for CYTK is shown in the Key Statistics section. This valuation metric helps compare Cytokinetics, Incorporated to industry peers.
Does CYTK pay dividends?
Cytokinetics, Incorporated does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for CYTK?
Based on ratings from 17 professional analysts over the last 90 days, the consensus for CYTK is Buy. The average 12-month price target is $111.21, a 78.4% upside from the Oct 22, 2026 close of $62.33.
What is the market cap of CYTK?
As of the Oct 22, 2026 close, Cytokinetics, Incorporated's market capitalization is $8.23B, classifying it as a mid-cap company. Cytokinetics, Incorporated operates in the Healthcare sector within the Biotechnology industry.